The content on this site is intended for healthcare professionals only
Dr Natalia Gandur speaks to ecancer about the key discussions and consensus themes that emerged from The Advanced Prostate Cancer Consensus Conference (APCCC) 2026.
She explains that the meeting focused on navigating areas of uncertainty in advanced prostate cancer, including treatment intensification, sequencing strategies, molecular testing, PSMA PET imaging, radioligand therapy, and the role of supportive care.
Dr Gandur discusses evolving approaches to metastatic hormone-sensitive and castration-resistant prostate cancer, highlighting the importance of patient selection, biomarker-driven treatment decisions, and the growing integration of genomic testing and PSMA-targeted therapies.
She also explores the challenges of treatment de-escalation, access to advanced diagnostics and therapeutics, frailty assessment, multidisciplinary care, and the need to align treatment choices with individual patient goals and healthcare resources.
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC
Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer
Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer
HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer
Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC
Innovation in cancer treatment and equity: ensuring emerging treatments reach all populations
Hammamet Declaration on Oncogenetics in Africa: African Oncogenetics Network
KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma
